The placebo effect in heart failure

Milton Packer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Many patients who are enrolled in controlled clinical trials of new drugs for the treatment of heart failure show favorable hemodynamic and clinical responses to placebo therapy. This "placebo effect" results from both the creation of a supportive therapeutic environment and the spontaneous improvement that is commonly seen when measurements of symptoms and cardiac function are repeated frequently over long intervals of time. Three months of treatment with a placebo produces a reduction in symptoms in 25% to 35% of patients, an increase in cardiac output and a decrease in pulmonary wedge pressure, and an increase in exercise tolerance of up to 90 to 120 seconds. Physicians commonly seek to maximize the "placebo effect", since the goal of treatment in the clinical setting is to improve the quality of the patient's life. On the other hand, clinical investigators seek to minimize the "placebo effect," since the goal of a research study is to test the hypothesis that the new drug is superior to a placebo.

Original languageEnglish (US)
Pages (from-to)1579-1582
Number of pages4
JournalAmerican Heart Journal
Volume121
Issue number3 PART II
DOIs
StatePublished - 1991

Fingerprint

Placebo Effect
Heart Failure
Placebos
Pulmonary Wedge Pressure
Exercise Tolerance
Controlled Clinical Trials
Therapeutics
Treatment Failure
Pharmaceutical Preparations
Cardiac Output
Hemodynamics
Quality of Life
Research Personnel
Physicians
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The placebo effect in heart failure. / Packer, Milton.

In: American Heart Journal, Vol. 121, No. 3 PART II, 1991, p. 1579-1582.

Research output: Contribution to journalArticle

Packer, Milton. / The placebo effect in heart failure. In: American Heart Journal. 1991 ; Vol. 121, No. 3 PART II. pp. 1579-1582.
@article{a717c9c3a7c842768f475523c53f43a6,
title = "The placebo effect in heart failure",
abstract = "Many patients who are enrolled in controlled clinical trials of new drugs for the treatment of heart failure show favorable hemodynamic and clinical responses to placebo therapy. This {"}placebo effect{"} results from both the creation of a supportive therapeutic environment and the spontaneous improvement that is commonly seen when measurements of symptoms and cardiac function are repeated frequently over long intervals of time. Three months of treatment with a placebo produces a reduction in symptoms in 25{\%} to 35{\%} of patients, an increase in cardiac output and a decrease in pulmonary wedge pressure, and an increase in exercise tolerance of up to 90 to 120 seconds. Physicians commonly seek to maximize the {"}placebo effect{"}, since the goal of treatment in the clinical setting is to improve the quality of the patient's life. On the other hand, clinical investigators seek to minimize the {"}placebo effect,{"} since the goal of a research study is to test the hypothesis that the new drug is superior to a placebo.",
author = "Milton Packer",
year = "1991",
doi = "10.1016/0002-8703(91)90062-3",
language = "English (US)",
volume = "121",
pages = "1579--1582",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3 PART II",

}

TY - JOUR

T1 - The placebo effect in heart failure

AU - Packer, Milton

PY - 1991

Y1 - 1991

N2 - Many patients who are enrolled in controlled clinical trials of new drugs for the treatment of heart failure show favorable hemodynamic and clinical responses to placebo therapy. This "placebo effect" results from both the creation of a supportive therapeutic environment and the spontaneous improvement that is commonly seen when measurements of symptoms and cardiac function are repeated frequently over long intervals of time. Three months of treatment with a placebo produces a reduction in symptoms in 25% to 35% of patients, an increase in cardiac output and a decrease in pulmonary wedge pressure, and an increase in exercise tolerance of up to 90 to 120 seconds. Physicians commonly seek to maximize the "placebo effect", since the goal of treatment in the clinical setting is to improve the quality of the patient's life. On the other hand, clinical investigators seek to minimize the "placebo effect," since the goal of a research study is to test the hypothesis that the new drug is superior to a placebo.

AB - Many patients who are enrolled in controlled clinical trials of new drugs for the treatment of heart failure show favorable hemodynamic and clinical responses to placebo therapy. This "placebo effect" results from both the creation of a supportive therapeutic environment and the spontaneous improvement that is commonly seen when measurements of symptoms and cardiac function are repeated frequently over long intervals of time. Three months of treatment with a placebo produces a reduction in symptoms in 25% to 35% of patients, an increase in cardiac output and a decrease in pulmonary wedge pressure, and an increase in exercise tolerance of up to 90 to 120 seconds. Physicians commonly seek to maximize the "placebo effect", since the goal of treatment in the clinical setting is to improve the quality of the patient's life. On the other hand, clinical investigators seek to minimize the "placebo effect," since the goal of a research study is to test the hypothesis that the new drug is superior to a placebo.

UR - http://www.scopus.com/inward/record.url?scp=27244462784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27244462784&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(91)90062-3

DO - 10.1016/0002-8703(91)90062-3

M3 - Article

AN - SCOPUS:27244462784

VL - 121

SP - 1579

EP - 1582

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3 PART II

ER -